Publications
Detailed Information
Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and beta III-Tubulin Between Primary Non-small Cell Lung Cancer and Metastatic Lymph Nodes and the Significance in Mid-Term Survival
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Chang Hyun | - |
dc.contributor.author | Jang, Bo Gun | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Chung, Doo Hyun | - |
dc.contributor.author | Kim, Young Tae | - |
dc.contributor.author | Jheon, Sanghoon | - |
dc.contributor.author | Sung, Sook-Whan | - |
dc.contributor.author | Kim, Joo Hyun | - |
dc.date.accessioned | 2020-04-27T11:40:38Z | - |
dc.date.available | 2020-04-27T11:40:38Z | - |
dc.date.created | 2020-02-19 | - |
dc.date.issued | 2009-11 | - |
dc.identifier.citation | Journal of Thoracic Oncology, Vol.4 No.11, pp.1307-1312 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.other | 91883 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165554 | - |
dc.description.abstract | Introduction: This study aimed to compare the expression profiles of excision repair crosscomplementation group 1 (ERCC1), x-ray repair crosscomplementation group 1 (XRCC1), and beta III-tubulin between patients with primary non-small cell lung cancer (NSCLC) and those with metastatic lymph nodes and to identify the prognostic significance of each chemotherapy resistance protein. Materials: Those who met the inclusion criteria were patients (1) with NSCLC, (2) with metastatic lymph nodes (N1 or N2), and (3) who underwent surgical resection followed by platinum-based adjuvant chemotherapy. A total of 82 patients were included in the study. The expression profile of each protein was evaluated by immunohistochemistry and compared according to tumor location. Results: The mean age of the patients was 57.5 +/- 8.4 years. There were 30 N1 and 52 N2 patients. ERCC I expression was upregulated in 55% and downregulated in 8% of metastatic lymph nodes, when compared with primary tumors (p < 0.05). XRCC1 was also upregulated in 56% and downregulated in 6% (p < 0.05). However, beta III-tubulin was upregulated in 12% and downregulated in 45% of patients (p < 0.05). beta III-tubulin expression in metastatic lymph nodes was greater in patients with adenocarcinoma than other cell types. Upregulation of ERCC1 in metastatic lymph nodes was a poor prognostic factor in N1 patients but not in N2 patients. Conclusions: Significant changes in the expression profile of each protein were observed in metastatic lymph nodes. The resistance protein-guided treatment Should be performed after integrative interpretation of expression profiles of each protein in both primary and metastatic sites. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier Inc. | - |
dc.title | Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and beta III-Tubulin Between Primary Non-small Cell Lung Cancer and Metastatic Lymph Nodes and the Significance in Mid-Term Survival | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 전상훈 | - |
dc.contributor.AlternativeAuthor | 김영태 | - |
dc.contributor.AlternativeAuthor | 성숙환 | - |
dc.contributor.AlternativeAuthor | 김주현 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 강창현 | - |
dc.contributor.AlternativeAuthor | 정두현 | - |
dc.identifier.doi | 10.1097/JTO.0b013e3181b9f236 | - |
dc.citation.journaltitle | Journal of Thoracic Oncology | - |
dc.identifier.wosid | 000271394000003 | - |
dc.identifier.scopusid | 2-s2.0-70449572285 | - |
dc.citation.endpage | 1312 | - |
dc.citation.number | 11 | - |
dc.citation.startpage | 1307 | - |
dc.citation.volume | 4 | - |
dc.identifier.sci | 000271394000003 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kang, Chang Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Chung, Doo Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Young Tae | - |
dc.contributor.affiliatedAuthor | Jheon, Sanghoon | - |
dc.contributor.affiliatedAuthor | Sung, Sook-Whan | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hyun | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | ERCC1 EXPRESSION | - |
dc.subject.keywordPlus | DRUG-RESISTANCE | - |
dc.subject.keywordPlus | DNA-REPAIR | - |
dc.subject.keywordPlus | STEM-CELLS | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Carcinoma | - |
dc.subject.keywordAuthor | Non-small cell | - |
dc.subject.keywordAuthor | Thoracic surgical procedures | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Adjuvant | - |
dc.subject.keywordAuthor | Drug resistance | - |
dc.subject.keywordAuthor | Neoplasm | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.